Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells
- 18 May 2015
- journal article
- research article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 116 (12) , 2824-2839
Abstract
BRCA1/2‐mutant cells are hypersensitive to inactivation of poly(ADP‐ribose) polymerase 1 (PARP‐1). We recently showed that inhibition of PARP‐1 by NU1025 is strongly cytotoxic for BRCA1‐positive BT‐20 cells, but not BRCA1‐deficient SKBr‐3 cells. These results raised the possibility that other PARP‐1 inhibitors, particularly those tested in clinical trials, may be more efficacious against BRCA1‐deficient SKBr‐3 breast cancer cells than NU1025. Thus, in the presented study the cytotoxicity of four PARP inhibitors under clinical evaluation (olaparib, rucaparib, iniparib and AZD2461) was examined and compared to that of NU1025. The sensitivity of breast cancer cells to the PARP‐1 inhibition strongly varied. Remarkably, BRCA‐1‐deficient SKBr‐3 cells were almost completely insensitive to NU1025, olaparib and rucaparib, whereas BRCA1‐expressing BT‐20 cells were strongly affected by NU1025 even at low doses. In contrast, iniparib and AZD2461 were cytotoxic for both BT‐20 and SKBr‐3 cells. Of the four tested PARP‐1 inhibitors only AZD2461 strongly affected cell cycle progression. Interestingly, the anti‐proliferative and pro‐apoptotic potential of the tested PARP‐1 inhibitors clearly correlated with their capacity to damage DNA. Further analyses revealed that proteomic signatures of the two studied breast cancer cell lines strongly differ, and a set of 197 proteins was differentially expressed in NU1025‐treated BT‐20 cancer cells. These results indicate that BT‐20 cells may harbor an unknown defect in DNA repair pathway(s) rendering them sensitive to PARP‐1 inhibition. They also imply that therapeutic applicability of PARP‐1 inhibitors is not limited to BRCA mutation carriers but can be extended to patients harboring deficiencies in other components of the pathway(s). J. Cell. Biochem. 116: 2824–2839, 2015.Keywords
Funding Information
- Österreichische Krebshilfe
This publication has 74 references indexed in Scilit:
- Proteome signatures of inflammatory activated primary human peripheral blood mononuclear cellsJournal of Proteomics, 2012
- PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cellsBiochemical Pharmacology, 2012
- The landscape of cancer genes and mutational processes in breast cancerNature, 2012
- Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In VitroClinical Cancer Research, 2012
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast CancerNew England Journal of Medicine, 2011
- Improved LC−MS/MS Spectral Counting Statistics by Recovering Low-Scoring Spectra Matched to Confidently Identified Peptide SequencesJournal of Proteome Research, 2010
- PARP inhibition: PARP1 and beyondNature Reviews Cancer, 2010
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsProceedings of the National Academy of Sciences, 2008
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001
- Identification of the breast cancer susceptibility gene BRCA2Nature, 1995